Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library

European Journal of Immunology

Volumn 43, Issue 2, 2013, Pages 499-509

  Zhou, Mingkui ^a   Meyer, Torsten ^b   Koch, Stefanie ^c   Koch, Joachim ^a   Von Briesen, Hagen ^c   Benito, José M ^d   Soriano, Vincent ^d   Haberl, Annette ^e   Bickel, Markus ^e   Dübel, Stefan ^b   Hust, Michael ^b   Dietrich, Ursula ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^c FRAUNHOFER INSTITUTE FOR BIOMEDICAL ENGINEERING   (Germany)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

Elite controllers; Epitopes; HIV 1; Neutralizing antibodies; Phage display

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; PHOSPHATIDYLSERINE;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR CLONING; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; BACTERIOPHAGES; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; PEPTIDE LIBRARY;

EID: 84873750975     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242974     Document Type: Article

References (85)

1. Mascola, J. R. and Montefiori, D. C., The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010. 28: 413-444.
2. Burton, D. R. and Weiss, R. A., AIDS/HIV. A boost for HIV vaccine design. Science 2010. 329: 770-773.
3. Hoxie, J. A., Toward an antibody-based HIV-1 vaccine. Annu. Rev. Med. 2010. 61: 135-152.
4. Burton, D. R. and Parren, P. W., Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? Nat. Med. 2000. 6: 123-125.
5. Guenaga, J., Dosenovic, P., Ofek, G., Baker, D., Schief, W. R., Kwong, P. D., Karlsson Hedestam, G. B. et al., Heterologous epitope-scaffold prime:boosting immuno-focuses B-cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 2011. 6: e16074.
6. Ho, J., Uger, R. A., Zwick, M. B., Luscher, M. A., Barber, B. H. and MacDonald, K. S., Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 2005. 23: 1559-1573.
7. Morris, L., Chen, X., Alam, M., Tomaras, G., Zhang, R., Marshall, D. J., Chen, B. et al., Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B-cell sorting. PLoS One 2011. 6: e23532.
8. Wahome, N., Pfeiffer, T., Ambiel, I., Yang, Y., Keppler, O. T., Bosch, V. and Burkhard, P., Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem. Biol. Drug Des. 2012. 80: 349-357.
9. Mikell, I., Sather, D. N., Kalams, S. A., Altfeld, M., Alter, G. and Stamatatos, L., Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011. 7: e1001251.
10. Saag, M. and Deeks, S. G., How do HIV elite controllers do what they do? Clin. Infect. Dis. 2010. 51: 239-241.
11. Pereyra, F., Jia, X., McLaren, P. J., Telenti, A., de Bakker, P. I., Walker, B. D., Ripke, S. et al., The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010. 330: 1551-1557.
12. Lambotte, O., Ferrari, G., Moog, C., Yates, N. L., Liao, H. X., Parks, R. J., Hicks, C. B. et al., Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009. 23: 897-906.
13. Humbert, M. and Dietrich, U., The role of neutralizing antibodies in HIV infection. AIDS Rev. 2006. 8: 51-59.
14. Humbert, M., Antoni, S., Brill, B., Landersz, M., Rodes, B., Soriano, V., Wintergerst, U. et al., Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur. J. Immunol. 2007. 37: 501-515.
15. Montefiori, D. C., Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 2009. 485: 395-405.
16. Kugler, J., Nieswandt, S., Gerlach, G. F., Meens, J., Schirrmann, T. and Hust, M., Identification of immunogenic polypeptides from a Mycoplasma hyopneumoniae genome library by phage display. Appl. Microbiol. Biotechnol. 2008. 80: 447-458.
17. Naseem, S., Meens, J., Jores, J., Heller, M., Dubel, S., Hust, M. and Gerlach, G. F., Phage display-based identification and potential diagnostic application of novel antigens from Mycoplasma mycoides subsp. mycoides small colony type. Vet. Microbiol. 2010. 142: 285-292.
18. Mehandru, S., Wrin, T., Galovich, J., Stiegler, G., Vcelar, B., Hurley, A., Hogan, C. et al., Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J. Virol. 2004. 78: 14039-14042.
19. Zwick, M. B., Labrijn, A. F., Wang, M., Spenlehauer, C., Saphire, E. O., Binley, J. M., Moore, J. P. et al., Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001. 75: 10892-10905.
20. Binley, J. M., Lybarger, E. A., Crooks, E. T., Seaman, M. S., Gray, E., Davis, K. L., Decker, J. M. et al., Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 2008. 82: 11651-11668.
21. Doria-Rose, N. A., Klein, R. M., Manion, M. M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C. W. et al., Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 2009. 83: 188-199.
22. Gray, E. S., Madiga, M. C., Moore, P. L., Mlisana, K., Abdool Karim, S. S., Binley, J. M., Shaw, G. M. et al., Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J. Virol. 2009. 83: 11265-11274.
23. Pietzsch, J., Scheid, J. F., Mouquet, H., Seaman, M. S., Broder, C. C. and Nussenzweig, M. C., Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J. Virol. 2010. 84: 5032-5042.
24. Tomaras, G. D., Binley, J. M., Gray, E. S., Crooks, E. T., Osawa, K., Moore, P. L., Tumba, N. et al., Polyclonal B-cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 2011. 85: 11502-11519.
25. Haynes, B. F., Fleming, J., St Clair, E. W., Katinger, H., Stiegler, G., Kunert, R., Robinson, J. et al., Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005. 308: 1906-1908.
26. Haynes, B. F., Moody, M. A., Verkoczy, L., Kelsoe, G. and Alam, S. M., Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 2005. 14: 59-67.
27. Dennison, S. M., Anasti, K., Scearce, R. M., Sutherland, L., Parks, R., Xia, S. M., Liao, H. X. et al., Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J. Virol. 2011. 85: 1340-1347.
28. Shen, X., Parks, R. J., Montefiori, D. C., Kirchherr, J. L., Keele, B. F., Decker, J. M., Blattner, W. A. et al., In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 2009. 83: 3617-3625.
29. Zhu, Z., Qin, H. R., Chen, W., Zhao, Q., Shen, X., Schutte, R., Wang, Y. et al., Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J. Virol. 2011. 85: 11401-11408.
30. Dhillon, A. K., Donners, H., Pantophlet, R., Johnson, W. E., Decker, J. M., Shaw, G. M., Lee, F. H. et al., Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 2007. 81: 6548-6562.
31. Earl, P. L., Broder, C. C., Doms, R. W. and Moss, B., Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol. 1997. 71: 2674-2684.
32. Stevenson, F. K., Smith, G. J., North, J., Hamblin, T. J. and Glennie, M. J., Identification of normal B-cell counterparts of neoplastic cells which secrete cold agglutinins of anti-I and anti-i specificity. Br. J. Haematol. 1989. 72: 9-15.
33. Zhu, M., Olee, T., Le, D. T., Roubey, R. A., Hahn, B. H., Woods, V. L., Jr. and Chen, P. P., Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br. J. Haematol. 1999. 105: 102-109.
34. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A. et al., Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 2000. 6: 200-206.
35. Ferrantelli, F., Hofmann-Lehmann, R., Rasmussen, R. A., Wang, T., Xu, W., Li, P. L., Montefiori, D. C. et al., Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003. 17: 301-309.
36. Hessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. et al., Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009. 15: 951-954.
37. Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K. et al., Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999. 73: 4009-4018.
38. Parren, P. W., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P. et al., Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001. 75: 8340-8347.
39. Ruprecht, R. M., Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol. Biol. 2009. 525: 559-566, xiv.
40. Shibata, R., Igarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, W., Willey, R. et al., Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 1999. 5: 204-210.
41. Hessell, A. J., Rakasz, E. G., Tehrani, D. M., Huber, M., Weisgrau, K. L., Landucci, G., Forthal, D. N. et al., Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 2010. 84: 1302-1313.
42. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J. et al., HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004. 5: 233-236.
43. Stamatatos, L., Morris, L., Burton, D. R. and Mascola, J. R., Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 2009. 15: 866-870.
44. Zolla-Pazner, S., Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 2004. 4: 199-210.
45. Burton, D. R., Poignard, P., Stanfield, R. L. and Wilson, I. A., Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012. 337: 183-186.
46. Chen, W. and Dimitrov, D. S., Monoclonal antibody-based candidate therapeutics against HIV type 1. AIDS Res. Hum. Retroviruses 2012. 28: 425-434.
47. Walker, L. M., Phogat, S. K., Chan-Hui, P. Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T. et al., Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009. 326: 285-289.
48. Bailey, J. R., Lassen, K. G., Yang, H.-C., Quinn, T. C., Ray, S. C., Blankson, J. N. and Siliciano, R. F., Neutralizing antibodies do not mediate suppression of human immunodeficiency virus Type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 2006. 80: 4758-4770.
49. Corti, D., Langedijk, J. P., Hinz, A., Seaman, M. S., Vanzetta, F., Fernandez-Rodriguez, B. M., Silacci, C. et al., Analysis of memory B-cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010. 5: e8805.
50. Moore, P. L., Gray, E. S., Sheward, D., Madiga, M., Ranchobe, N., Lai, Z., Honnen, W. J. et al., Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 2011. 85: 3128-3141.
51. Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G. et al., Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009. 458: 636-640.
52. Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., Zhou, T. et al., Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010. 329: 856-861.
53. Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K. et al., Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011. 477: 466-470.
54. Enshell-Seijffers, D., Denisov, D., Groisman, B., Smelyanski, L., Meyuhas, R., Gross, G., Denisova, G. et al., The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J. Mol. Biol. 2003. 334: 87-101.
55. Enshell-Seijffers, D., Smelyanski, L., Vardinon, N., Yust, I. and Gershoni, J. M., Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV+ individuals. FASEB J. 2001. 15: 2112-2120.
56. Humbert, M., Rasmussen, R. A., Ong, H., Kaiser, F. M., Hu, S. L. and Ruprecht, R. M., Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One 2008. 3: e3937.
57. Zhang, M. Y. and Dimitrov, D. S., Sequential antigen panning for selection of broadly cross-reactive HIV-1-neutralizing human monoclonal antibodies. Methods Mol. Biol. 2009. 562: 143-154.
58. Zhang, M. Y., Vu, B. K., Choudhary, A., Lu, H., Humbert, M., Ong, H., Alam, M. et al., Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J. Virol. 2008. 82: 6869-6879.
59. Li, Y., Migueles, S. A., Welcher, B., Svehla, K., Phogat, A., Louder, M. K., Wu, X. et al., Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 2007. 13: 1032-1034.
60. Sather, D. N. and Stamatatos, L., Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 2010. 28(Suppl 2): B8-B12.
61. Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X. et al., Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009. 83: 757-769.
62. Alam, S. M., Scearce, R. M., Parks, R. J., Plonk, K., Plonk, S. G., Sutherland, L. L., Gorny, M. K. et al., Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 2008. 82: 115-125.
63. Alam, S. M., Morelli, M., Dennison, S. M., Liao, H. X., Zhang, R., Xia, S. M., Rits-Volloch, S. et al., Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 2009. 106: 20234-20239.
64. Montero, M., van Houten, N. E., Wang, X. and Scott, J. K., The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 2008. 72: 54-84, table of contents.
65. Muster, T., Guinea, R., Trkola, A., Purtscher, M., Klima, A., Steindl, F., Palese, P. et al., Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 1994. 68: 4031-4034.
66. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Ruker, F. et al., A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993. 67: 6642-6647.
67. Zwick, M. B., Wang, M., Poignard, P., Stiegler, G., Katinger, H., Burton, D. R. and Parren, P. W., Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 2001. 75: 12198-12208.
68. Montero, M., Gulzar, N., Klaric, K. A., Donald, J. E., Lepik, C., Wu, S., Tsai, S. et al., Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J. Virol. 2012. 86: 2930-2941.
69. Kim, M., Sun, Z. Y., Rand, K. D., Shi, X., Song, L., Cheng, Y., Fahmy, A. F. et al., Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat. Struct. Mol. Biol. 2011. 18: 1235-1243.
70. Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H. et al., Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012. 491: 406-412.
71. Miller, M. D., Geleziunas, R., Bianchi, E., Lennard, S., Hrin, R., Zhang, H., Lu, M. et al., A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. USA 2005. 102: 14759-14764.
72. Gustchina, E., Louis, J. M., Lam, S. N., Bewley, C. A. and Clore, G. M., A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J. Virol. 2007. 81: 12946-12953.
73. Sabin, C., Corti, D., Buzon, V., Seaman, M. S., Lutje Hulsik, D., Hinz, A., Vanzetta, F. et al., Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog. 2010. 6: e1001195.
74. Tomaras, G. D. and Haynes, B. F., HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr. Opin. HIV AIDS 2009. 4: 373-379.
75. Gach, J. S., Leaman, D. P. and Zwick, M. B., Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Curr. Top Med. Chem. 2011. 11: 2997-3021.
76. Diomede, L., Nyoka, S., Pastori, C., Scotti, L., Zambon, A., Sherman, G., Gray, C. M. et al., Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. J. Virol. 2012. 86: 4129-4138.
77. Zhu, Z., Qin, H. R., Chen, W., Zhao, Q., Fouda, G., Schutte, R., Shen, X. et al., New broadly neutralizing human monoclonal antibodies targeting the 2F5 epitope. AIDS Res. Hum. Retroviruses 2010. 26: A14-A15.
78. Bryson, S., Julien, J. P., Hynes, R. C. and Pai, E. F., Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J. Virol. 2009. 83: 11862-11875.
79. Zolla-Pazner, S., Cohen, S., Pinter, A., Krachmarov, C., Wrin, T., Wang, S. and Lu, S., Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 2009. 392: 82-93.
80. Zhou, M., Kostoula, I., Brill, B., Panou, E., Sakarellos-Daitsiotis, M. and Dietrich, U., Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. Vaccine 2012. 30: 1911-1916.
81. Rondot, S., Koch, J., Breitling, F. and Dubel, S., A helper phage to improve single-chain antibody presentation in phage display. Nat. Biotechnol. 2001. 19: 75-78.
82. Soltes, G., Hust, M., Ng, K. K., Bansal, A., Field, J., Stewart, D. I., Dubel, S. et al., On the influence of vector design on antibody phage display. J. Biotechnol. 2007. 127: 626-637.
83. Schirrmann, T. and Hust, M., Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol. Biol. 2010. 651: 177-209.
84. Hust, M., Dubel, S. and Schirrmann, T., Selection of recombinant antibodies from antibody gene libraries. Methods Mol. Biol. 2007. 408: 243-255.
85. Brandt, O., Dietrich, U. and Koch, J., Solid-supported peptide arrays in the investigation of protein-protein and protein-nucleic acid interactions. Curr. Chem. Biol. 2009. 3: 171-179.